Vidal C, García F, Romeu J, Ruiz L, Miró J M, Cruceta A, Soriano A, Pumarola T, Clotet B, Gatell J M
Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic, Faculty of Medicine, University of Barcelona, Spain.
AIDS. 1998 Jul 30;12(11):1285-9. doi: 10.1097/00002030-199811000-00009.
To address the question of whether individuals with chronic HIV-1 infection have a stable viral load set-point and to assess the influence of host and viral factors on the evolution of viral load in a subset of stable asymptomatic patients with a baseline viral load below 5000 copies/ml and CD4+ T-cell count above 500 x 10(6)/l.
Medical visits were performed at least every 6 months including routine blood analysis, viral load and CD4+ T-cell count. HIV-1 RNA was measured in frozen (-70 degrees C) plasma samples using PCR. Patients were classified into three groups according to baseline viral load: group A, < 200 copies/ml (undetectable); group B, 201-2000 copies/ml; group C, 2001-5000 copies/ml. A survival analysis and a Cox regression model were performed to assess the influence of viral and host factors in the increase of baseline viral load. The endpoint was the time to increase viral load to a stable level > 0.5 log10 copies/ml above baseline viral load in groups B and C and to a stable detectable viral load (> 200 copies/ml) in group A.
A cohort of 114 patients with viral load below 5000 copies/ml was followed for a median of 12 months (6-42 months). Overall, 22 (19%) out of 114 patients had an increase > 0.5 log10 copies/ml of baseline viral load. Baseline viral load increased in two (5%) out of 37 patients in group A, four (12%) out of 33 patients in group B, and 16 (36%) out of 44 patients in group C (survival analysis, P<0.002). Patients of group C had a eightfold higher risk of increasing baseline viral load than patients in the other two groups pooled together (hazards ratio, 8.28; 95% confidence interval, 1.78-38; P = 0.006). Patients with an increase of viral load to the virological endpoint had a threefold higher risk of decreasing baseline CD4+ T-cell counts > 100 x 10(6)/I than patients with stable viral load (hazards ratio, 2.78; 95% confidence interval, 1.12-14; P = 0.03).
In our cohort of chronically HIV-1-infected asymptomatic patients with a baseline viral load < 5000 copies/ml and CD4+ cell count > 500 x 10(6)/l, a true viral load set-point did not seem to exist. Patients with baseline viral load of 2000-5000 copies/ml had an eightfold higher risk of increasing the level of viral load than patients with a baseline viral load below 2000 copies/ml.
探讨慢性HIV-1感染个体是否具有稳定的病毒载量设定点,并评估宿主和病毒因素对一部分基线病毒载量低于5000拷贝/毫升且CD4+T细胞计数高于500×10⁶/升的稳定无症状患者病毒载量演变的影响。
至少每6个月进行一次医疗随访,包括常规血液分析、病毒载量和CD4+T细胞计数。使用PCR检测冷冻(-70℃)血浆样本中的HIV-1 RNA。根据基线病毒载量将患者分为三组:A组,<200拷贝/毫升(检测不到);B组,201-2000拷贝/毫升;C组,2001-5000拷贝/毫升。进行生存分析和Cox回归模型以评估病毒和宿主因素对基线病毒载量增加的影响。终点是B组和C组病毒载量增加至比基线病毒载量高>0.5 log₁₀拷贝/毫升的稳定水平以及A组增加至稳定可检测病毒载量(>200拷贝/毫升)的时间。
对114例病毒载量低于5000拷贝/毫升的患者进行了中位时间为12个月(6-42个月)的随访。总体而言,114例患者中有22例(19%)基线病毒载量增加>0.5 log₁₀拷贝/毫升。A组37例患者中有2例(5%)基线病毒载量增加,B组33例患者中有4例(12%),C组44例患者中有16例(36%)(生存分析,P<0.002)。C组患者基线病毒载量增加的风险比其他两组合并患者高8倍(风险比,8.28;95%置信区间,1.78-38;P = 0.006)。病毒载量增加至病毒学终点的患者基线CD4+T细胞计数降低>100×10⁶/升的风险比病毒载量稳定的患者高2倍(风险比,2.78;95%置信区间,1.12-14;P = 0.03)。
在我们这组基线病毒载量<5000拷贝/毫升且CD4+细胞计数>500×10⁶/升的慢性HIV-1感染无症状患者中,似乎不存在真正的病毒载量设定点。基线病毒载量为2000-5000拷贝/毫升的患者病毒载量水平增加的风险比基线病毒载量低于2000拷贝/毫升的患者高8倍。